Kantar Health Blog

  • Veni, Vedi, Vene? Venetoclax hopes to conquer CLL

    by Stephanie Hawthorne | Dec 8, 2015
    Stephanie Hawthorne
    Oncology Conference Insight --- ASH 2015: Treatment of chronic lymphocytic leukemia (CLL) has enjoyed somewhat of a renaissance in the past couple of years. Until recently, therapy for both front-line and relapsed disease usually consisted of a Rituxan-based regimen often in combination with chemotherapy agents such as fludarabine or Treanda.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2015 --- The field of immunotherapy in oncology has exploded in the last few years, particularly in the case of immune checkpoint inhibitors, which block the immune system’s “brakes” by inhibiting either CTLA-4, PD-L1, PD-L2 or PD-1 (although inhibitors of other immune checkpoint molecules are also in early stages of development).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2015 --- Cytarabine-based intensive chemotherapy remains standard of care for patients with acute myeloid leukemia (AML); however, about 70% of patients will relapse within five years of initial therapy, thus highlighting the need for development of more efficacious regimens.1 While therapy has traditionally consisted of a “one-size-fits-all” concept, it is better appreciated that AML is a rather heterogeneous disease comprising various subtypes with complex genetic and chromosomal changes.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2015 --- Without a doubt, PD-1 and PD-L1 inhibitors have taken the oncology field by storm. With its approval in Japan in July 2014 for unresectable melanoma, Opdivo® (nivolumab, Bristol-Myers Squibb/Ono Pharmaceuticals) was the first PD-1 inhibitor to be approved worldwide and represented the culmination of a longstanding quest to harness the body’s inherent immune system to combat cancer.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ECC 2015 --- Sutent® (sunitinib, Pfizer) and Votrient® (pazopanib, Novartis) are currently considered the standards of care for first-line therapy in renal cell carcinoma (RCC). However, neither drug (nor any other agents currently approved) has been able to show an overall survival (OS) benefit in clinical trials; they were approved by regulatory agencies based on a significant improvement in progression-free survival (PFS).
    Continue Reading > | Go comment! | Share